NEW YORK (GenomeWeb) – Illumina has struck a deal with Harvard Pilgrim Health Care to provide noninvasive prenatal testing to women with average-risk pregnancies. The nonprofit health services company covers around 1.2 million people in Massachusetts, Connecticut, New Hampshire, and Maine.

Under the terms of the value-based contract, Harvard Pilgrim will cover NIPT for average-risk pregnancies. However, if one-year costs of testing exceed a pre-established baseline, Illumina will reimburse Harvard Pilgrim for the costs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar
26
Sponsored by
PerkinElmer

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.